USPTO Patent Grant: Daprodustat Crystal Form M Preparation and Use

The United States Patent and Trademark Office (USPTO) has issued patent US12583823B2, granting exclusive rights to Shenzhen Jingtai Technology Co., LTD. for crystal form M of daprodustat. This patent specifically details the characteristics of crystal form M, including its X-ray powder diffraction pattern, and outlines its preparation method and intended uses. The claimed crystal form is noted for its good light, temperature, and humidity stability, as well as favorable solubility and high purity.

This patent grant signifies the protection of intellectual property related to a specific pharmaceutical compound. While it does not impose direct compliance obligations on other entities, it establishes exclusive rights for the assignee. Companies involved in the development, manufacturing, or sale of daprodustat or related compounds should be aware of this patent to avoid infringement. The patent's effective date is March 24, 2026, with a filing date of February 18, 2022.